Person

Back to overview

Rieben Robert

Gender Male
Institute Department for BioMedical Research Universität Bern
ORCID 0000-0003-4179-8891
Show all

Projects as responsible applicant

Responsible applicant Institution of higher education Start End date Funding scheme

Endothelial cell protection and attenuation of innate immunity in ischemia/reperfusion injury and organ transplantation
Rieben Robert University of Berne - BE 01.05.2007 30.04.2010 Project funding (Div. I-III)

Xeno2Cure - advanced engineering and testing of organ donor pigs
Rieben Robert University of Berne - BE 01.04.2021 31.03.2025 Sinergia

New Synthetic ABO-Immunoabsorbents: in Vitro Evaluation of Effi- cacy and Biocompatibility.
Rieben Robert University of Berne - BE 04.09.1993 03.10.1993 International short research visits

Characterization of xenoantigens and -antibodies in the pig-to- human and guinea-pig/hamster-to-rat models.
Rieben Robert Institution abroad - IACH 01.03.1995 31.12.1996 Fellowships for advanced researchers

Endothelial cell protection in ischemia / reperfusion injury: Investigation into the roles of the glycocalyx and the plasma cascade systems
Rieben Robert University of Berne - BE 01.12.2018 30.11.2022 Project funding (Div. I-III)

Synthetic carbohydrates and neo-glycoconjugates: Design and application as tools to assess molecular aspects of xenotransplantation
Rieben Robert University of Berne - BE 01.10.2000 30.09.2003 SCOPES

Endothelial cell protection: The role of heparan sulfate proteoglycans and complement in pathophysiology and prevention of ischemia / reperfusion injury
Rieben Robert University of Berne - BE 01.04.2011 30.09.2014 Project funding (Div. I-III)

Endothelial cell protection in xenotransplantation and ischemia / reperfusion injury: Assessing the effect of multiple transgenes and the pathophysiological role of the plasma cascade systems
Rieben Robert University of Berne - BE 01.10.2014 30.09.2017 Project funding (Div. I-III)

Effect of a locally delivered immunosuppressives encapsulated in self-assembled hydrogel systems on vascularized composite allotransplantation
Rieben Robert University of Berne - BE 01.04.2015 30.09.2018 India

Endothelial cell protection in ischemia / reperfusion injury and acute vascular xenograft rejection.
Rieben Robert University of Berne - BE 01.04.2004 31.03.2007 Project funding (Div. I-III)

Projects as co-applicant

Responsible applicant Institution of higher education Start End date Funding scheme

Site-specific immunosuppression for long-term maintenance of vascularized composite allotransplantation: validation of efficacy and safety in a clinically relevant large animal model
Olariu Radu University of Berne - BE 01.04.2019 31.03.2023 Project funding (Div. I-III)

Unravelling consequences of SARS-CoV-2 mediated inflammatory immune responses in heart and vasculature
Döring Yvonne University of Berne - BE 01.11.2020 31.10.2022 NRP 78 Covid-19

Composite tissue preservation by extracorporeal blood perfusion and vascular cytoprotection to extend the time limit to replantation or transplantation
Vögelin Esther University of Berne - BE 01.07.2012 31.12.2015 Project funding (Div. I-III)

ABO-incompatibility and hyperacute xenograft rejection
Seebach Jörg Dieter University of Zurich - ZH 01.10.2000 30.09.2005 NRP 46 Implants and Transplants

Microscopy Equipment for Organ-on-Chips and Perfused Microfluidic Systems with High Speed Camera
Guenat Olivier University of Berne - BE 01.12.2014 30.11.2016 R'EQUIP

Projects as member of staff

Responsible applicant Institution of higher education Start End date Funding scheme

Antigen-specifity and subclass distribution of platelet- associated IgG - departure from distribution of serum IgG?
Nydegger Urs University of Berne - BE 01.04.1990 31.03.1993 Project funding (Div. I-III)

Projects as project partner

Responsible applicant Institution of higher education Start End date Funding scheme

Sweet control: Sialoglycans in cell-mediated anti-tumor responses
von Gunten Stephan University of Berne - BE 01.04.2019 31.03.2023 Project funding (Div. I-III)

Antibody-dependent innate immune cell functions in autoimmunity and monoclonal antibody therapies
Seebach Jörg Dieter University of Geneva - GE 01.10.2021 30.09.2025 Project funding (Div. I-III)

„Beta-adrenergic regulation of gut-vascular barrier (GVB): impact on gut-liver-axis and susceptibility for acute-on-chronic liver failure (ACLF) in cirrhotic mice
Wiest Reiner University of Berne - BE 01.08.2020 31.07.2023 Project funding (Div. I-III)

-